JPWO2020205498A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020205498A5
JPWO2020205498A5 JP2021557925A JP2021557925A JPWO2020205498A5 JP WO2020205498 A5 JPWO2020205498 A5 JP WO2020205498A5 JP 2021557925 A JP2021557925 A JP 2021557925A JP 2021557925 A JP2021557925 A JP 2021557925A JP WO2020205498 A5 JPWO2020205498 A5 JP WO2020205498A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
pharmaceutically acceptable
hexenoyl
ghrh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527190A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025180 external-priority patent/WO2020205498A1/en
Publication of JP2022527190A publication Critical patent/JP2022527190A/ja
Publication of JPWO2020205498A5 publication Critical patent/JPWO2020205498A5/ja
Pending legal-status Critical Current

Links

JP2021557925A 2019-03-29 2020-03-27 肝疾患の治療で使用するためのｇｈｒｈまたはその類似物 Pending JP2022527190A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962826284P 2019-03-29 2019-03-29
US62/826,284 2019-03-29
US201962861187P 2019-06-13 2019-06-13
US62/861,187 2019-06-13
PCT/US2020/025180 WO2020205498A1 (en) 2019-03-29 2020-03-27 Ghrh or analogues thereof for use in treatment of hepatic disease

Publications (2)

Publication Number Publication Date
JP2022527190A JP2022527190A (ja) 2022-05-31
JPWO2020205498A5 true JPWO2020205498A5 (no) 2023-04-05

Family

ID=72607731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557925A Pending JP2022527190A (ja) 2019-03-29 2020-03-27 肝疾患の治療で使用するためのｇｈｒｈまたはその類似物

Country Status (10)

Country Link
US (4) US10799562B1 (no)
EP (1) EP3947426A4 (no)
JP (1) JP2022527190A (no)
KR (1) KR20210145226A (no)
CN (1) CN113646327A (no)
AU (1) AU2020253828A1 (no)
CA (1) CA3133319A1 (no)
IL (1) IL286703A (no)
SG (1) SG11202110469PA (no)
WO (1) WO2020205498A1 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020253828A1 (en) 2019-03-29 2021-10-28 The General Hospital Corporation GHRH or analogues thereof for use in treatment of hepatic disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678083A (zh) * 2007-04-04 2010-03-24 瑟瑞技术公司 Ghrh分子的药物制剂
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US20150174207A1 (en) * 2013-12-24 2015-06-25 University Of Miami Methods for treating cancer with ghrh agonists
WO2017066619A1 (en) * 2015-10-16 2017-04-20 Teva Pharmaceutical Industries Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
US9988428B2 (en) * 2016-04-19 2018-06-05 Griffon Pharmaceuticals Inc. Pegylated bioactive peptides and uses thereof
EA202091464A1 (ru) * 2018-02-14 2020-12-07 Люмос Фарма, Инк. Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита
AU2020253828A1 (en) * 2019-03-29 2021-10-28 The General Hospital Corporation GHRH or analogues thereof for use in treatment of hepatic disease
KR20230097095A (ko) * 2020-10-30 2023-06-30 더 제너럴 하스피탈 코포레이션 간 질환의 평가를 위한 키트, 시약 및 방법
AU2021379921A1 (en) * 2020-11-16 2023-07-06 The Regents Of The University Of California Use of pharmaceutical doses of niacin, or an analog thereof, for the regression or reversal of fibrosis and/or liver cirrhosis

Similar Documents

Publication Publication Date Title
Negroni et al. Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans
JP7491839B2 (ja) 長期作用型の変異ヒト由来線維芽細胞増殖因子の新規な用途
Dignam et al. Effects of estrogens on renal hemodynamics and excretion of electrolytes in human subjects
EP1369119B1 (en) Il-12 expression controlling agents
WO2016173486A1 (zh) 曲美他嗪在制备防治肝病的药物中的用途
CN107213149B (zh) 青蒿素类衍生物在制备治疗或辅助治疗自身免疫性甲状腺疾病药物中的用途
US4916117A (en) Treatment of inflammation using alpha 1-antichymotrypsin
WO2023109747A1 (zh) 2,4-二羟基苯甲酸在治疗铁过载疾病药品中的应用
WO2001010387A2 (en) Antiviral therapy use of p-glycoprotein modulators
CN111904970B (zh) 白头翁皂苷b4在制备治疗哮喘的药物中的用途
WO2019134159A1 (zh) 一种白头翁皂苷b4的直肠粘膜给药制剂及其制备方法
CN113069445A (zh) 牛防风素作为有效成分在制备乙型肝炎治疗药物中的用途
US11278542B2 (en) Use of nicotinamide composition in preparation of drug for treating hand-foot skin reaction induced by sorafenib
JPWO2020205498A5 (no)
CN109846863B (zh) 和厚朴酚的用途
Pajus et al. Erythroderma after clodronate treatment.
KR101086040B1 (ko) 간섬유화 및 간경화 치료 효과를 갖는 아시아트산 유도체
CN114306332B (zh) 塔拉萨敏在制备治疗关节炎药物中的应用
CN114159435B (zh) 附子灵在制备治疗关节炎药物中的应用
NL8203316A (nl) Farmaceutische preparaten met menselijk pro-insuline.
RU2785582C2 (ru) Применение пегилированного рекомбинантного химерного фактора роста фибробластов-21 мыши или его фармацевтически приемлемой соли в составе лекарственных средств для лечения неалкогольного стеатогепатита
JP3014119B2 (ja) 直腸投与用赤血球造血剤
CN115501236B (zh) 一种醋酸烯诺孕酮在制备降低肺部炎症性疾病的药物中的应用
KR0129798B1 (ko) 간염의 예방 및 치료용 의약 조성물
Hilton Rate of the Enzymatic Breakdown of Digitoxin.